Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2025-12-22 Share Issue/Capital Cha…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - MYX 6 pages 18.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance and conversion of unquoted options and convertible securities into ordinary shares. It includes specific information about the securities issued, dates, and mentions that some securities were issued under an employee incentive scheme. The document is a formal notification of securities issuance and conversion, consistent with announcements related to share issues or capital changes. It does not contain financial statements, management discussion, or audit information. It is not a report or presentation but a regulatory announcement about securities issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (7120 characters) and content confirm it is not a mere announcement of a report but a substantive notification of capital changes.
2025-12-22 English
Notification of cessation of securities - MYX 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights (unquoted equity securities) for Mayne Pharma Group Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. This type of document is a formal announcement to the ASX about changes in the company's securities, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or audit information. It is not a report but a regulatory announcement about securities cessation. According to the filing definitions, this fits best under 'Regulatory Filings (RNS)' as a general regulatory announcement that does not fit into more specific categories like share issue or capital change (SHA) or director dealings (DIRS). The document length is under 5,000 characters and is a direct announcement, not a report publication announcement. Therefore, the classification is RNS with high confidence.
2025-12-22 English
Change of Director's Interest Notice 3 pages 333.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and performance rights acquired and disposed of, dates of changes, and nature of transactions. This type of document is a formal notification of personal share transactions by a company director, commonly known as a director's dealing notice. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a certification but a detailed notice of insider transactions.
2025-12-22 English
Market Update 3 pages 243.0KB
Earnings Release Classification · 95% confidence The document is an ASX announcement titled 'MARKET UPDATE' and 'UNAUDITED RESULTS' for the first five months of the fiscal year 2026 (July to November 2025). It provides detailed financial and operational performance data, including revenue, EBITDA, segment contributions, and outlook commentary. The document is about 9,219 characters long, which is substantial and contains actual financial data and analysis rather than just a brief summary or a notice of report publication. It is not a full annual report (10-K) or interim report (IR) but rather a trading update with unaudited results and market commentary. This type of document typically fits best under the category of Earnings Release (ER), as it announces initial quarterly/periodical financial results with key highlights and operational updates. It is not a full interim report with comprehensive financial statements, so IR is less appropriate. It is also not a regulatory filing or report publication announcement since it contains substantive financial data and outlook. Therefore, the most appropriate classification is Earnings Release (ER). Q2 2026
2025-12-21 English
2025 Notice of Annual General Meeting and shareholder pack 17 pages 1.3MB
AGM Information Classification · 100% confidence The document is a detailed notice and invitation to the 2025 Annual General Meeting (AGM) of Mayne Pharma Group Limited. It includes the date and time of the AGM, instructions for participation (both in person and online), proxy voting details, and the agenda items for the meeting such as consideration of statutory reports, re-election of directors, adoption of the remuneration report, and approval of a long-term incentive grant. The document also contains voting restrictions and proxy information. There is no actual financial data or results presented, nor is this a transcript or a report publication announcement. The content is consistent with materials typically distributed to shareholders ahead of an AGM to inform them about the meeting and solicit their participation and votes. Therefore, this document fits the category of AGM Information (AGM-R).
2025-12-21 English
MYX officially opens newly expanded manufacturing facility 2 pages 377.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the official opening of a newly expanded manufacturing facility by Mayne Pharma. It includes details about the facility, investment, government grants, and some financial figures for FY25. The document is relatively short (3097 characters) and focuses on a corporate event and operational update rather than detailed financial statements or regulatory filings. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is also not a call transcript, management change, or legal proceeding. The content fits best as a general regulatory announcement about company operations and capital investment, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2025-12-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.